Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Roche Holding AG Gets Swiss Approval For Skin Cancer Drug-Reuters


Tuesday, 11 Jun 2013 01:24am EDT 

Reuters reported that Roche Holding AG has received Swiss approval for Erivedge, the medicine for people with advanced forms of basal cell carcinoma, the common skin cancer. 

Company Quote

36.355
-0.035 -0.10%
22 Oct 2014